New Treatment of Alopecia Areata

Alopecia Areata Clinical Trial

Official title: Efficacy of Trichloroacetic Acid in Patients of Alopecia Areata : Clinico-histopathological Study

Status Completed

Clinical Trial Summary

Abstract: Alopecia areata is believed to be an autoimmune disease resulting from a breach in the immune privilege of the hair follicles causing non scarring hair loss.

Methods: our study included 40 patients from may 2019 to july 2022 diagnosed clinically, dermatoscopically and pathologically as alopecia areata Data were enrolled from department of dermatology and venereology, Al-Hussein hospital.

Clinical Trial Description

For each patient the following will be done :

1. History taking including ( age, sex, disease duration, family history, history of drug intake, smoking and history of any associated disease ).

2. All patients will give a written, informed consent for induction.

3. Basic photographs will be taken to assess site, size (by cm), number, Extent of the patch using D5300 camera with lens (18-55).

4. Patients will be subjected to 3 session of trichloroacetic acid (TCA) 35% one month apart.

5. serial photographs and dermoscopic examination every month will be done and patient will be score.

6. Efficacy will be assessed using prognostic scoring system for density, pigmentation, and texture of growing hair.

7. histopathological examination will be done before the first session and one month after third session. ;

Related Conditions & MeSH terms

• Alopecia
• Alopecia Areata

• NCT number: NCT05594316
• Study type: Interventional
• Source: Al-Azhar University
• Status: Completed
• Phase: N/A
• Start date: May 1, 2019
• Completion date: October 19, 2022